These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22906932)

  • 1. Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.
    Chotirosniramit N; Sugandhavesa P; Aurpibul L; Thetket S; Kosashunhanan N; Supindham T; Wongkulab P; Kaewpoowat Q; Chaiklang K; Kaewthip O; Sroysuwan P; Wongthanee A; Lerdsamran H; Puthavathana P; Suparatpinyo K
    Hum Vaccin Immunother; 2012 Dec; 8(12):1854-9. PubMed ID: 22906932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Phongsamart W; Sirisanthana V; Wittawatmongkol O; Maleesatharn A; Sudjaritruk T; Chearskul P; Aurpibul L; Sirisanthana T; Chokephaibulkit K
    Vaccine; 2011 Nov; 29(47):8705-11. PubMed ID: 21893147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.
    Crum-Cianflone NF; Iverson E; Defang G; Blair PJ; Eberly LE; Maguire J; Ganesan A; Faix D; Duplessis C; Lalani T; Whitman T; Brandt C; Macalino G; Millar EV; Burgess T
    Vaccine; 2011 Apr; 29(17):3183-91. PubMed ID: 21371580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
    Soonawala D; Rimmelzwaan GF; Gelinck LB; Visser LG; Kroon FP
    PLoS One; 2011 Jan; 6(1):e16496. PubMed ID: 21304982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.
    Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M
    Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
    Lagler H; Grabmeier-Pfistershammer K; Touzeau-Römer V; Tobudic S; Ramharter M; Wenisch J; Gualdoni GA; Redlberger-Fritz M; Popow-Kraupp T; Rieger A; Burgmann H
    PLoS One; 2012; 7(5):e36773. PubMed ID: 22629330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
    Leahy TR; Goode M; Lynam P; Gavin PJ; Butler KM
    Influenza Other Respir Viruses; 2014 May; 8(3):360-6. PubMed ID: 24548473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
    Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.
    Viganò A; Giacomet V; Pariani E; Giani E; Manfredini V; Bedogni G; Erba P; Amendola A; Zanetti A; Zuccotti G
    Clin Vaccine Immunol; 2011 Sep; 18(9):1503-9. PubMed ID: 21795458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
    Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
    J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
    Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
    Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.
    Crum-Cianflone NF; Eberly LE; Duplessis C; Maguire J; Ganesan A; Faix D; Defang G; Bai Y; Iverson E; Lalani T; Whitman T; Blair PJ; Brandt C; Macalino G; Burgess T
    Clin Infect Dis; 2011 Jan; 52(1):138-46. PubMed ID: 21148532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.
    Okike IO; Yung C; Ladhani S; Oeser C; Bennett A; Doerholt K; Storey S; Donaghy S; Butter N; Hoschler K; Sheasby L; Heath PT; Miller E
    Vaccine; 2011 Sep; 29(38):6636-40. PubMed ID: 21742005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.
    Hatakeyama S; Iwatsuki-Horimoto K; Okamoto K; Nukui Y; Yata N; Fujita A; Inaba S; Yotsuyanagi H; Kawaoka Y
    Vaccine; 2011 Nov; 29(49):9224-8. PubMed ID: 21978767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.